HC Wainwright Lifts Earnings Estimates for Coya Therapeutics

Key Points

• HC Wainwright maintained its Buy rating and raised Coya Therapeutics’ Q3 2026 EPS estimate to a loss of $0.33 from $0.40, while lifting its FY2026 forecast to a loss of $1.30 from $1.52.
• Coya reported a quarterly loss of $0.28 per share, beating the $0.35 consensus estimate, and generated $0.24 million in revenue versus expectations of $0.13 million.
• Analyst sentiment remains broadly positive, with six Buy ratings and one Sell rating and an average price target of $15.33 versus the referenced share price of $5.04; however, the company continues to face significant losses and profitability risks.

Coya Therapeutics, Inc. (NASDAQ:COYA - Free Report) - Equities researchers at HC Wainwright boosted their Q3 2026 EPS estimates for shares of Coya Therapeutics in a research report issued to clients and investors on Monday, August 24th. HC Wainwright analyst R. Selvaraju now anticipates that the company will earn ($0.33) per share for the quarter, up from their prior estimate of ($0.40). HC Wainwright has a "Buy" rating on the stock. The consensus estimate for Coya Therapeutics' current full-year earnings is ($1.44) per share. HC Wainwright also issued estimates for Coya Therapeutics' Q4 2026 earnings at ($0.36) EPS, FY2026 earnings at ($1.30) EPS, Q1 2027 earnings at ($0.44) EPS, Q2 2027 earnings at ($0.48) EPS, Q3 2027 earnings at ($0.40) EPS, Q4 2027 earnings at ($0.33) EPS and FY2027 earnings at ($1.64) EPS.

Coya Therapeutics (NASDAQ:COYA - Get Free Report) last released its earnings results on Tuesday, August 11th. The company reported ($0.28) EPS for the quarter, beating analysts' consensus estimates of ($0.35) by $0.07. The company had revenue of $0.24 million during the quarter, compared to the consensus estimate of $0.13 million. Coya Therapeutics had a negative return on equity of 52.05% and a negative net margin of 270.22%.

A number of other equities analysts have also weighed in on the stock. Weiss Ratings reissued a "sell (d-)" rating on shares of Coya Therapeutics in a research report on Friday, July 17th. Chardan Capital reaffirmed a "buy" rating and issued a $14.00 target price on shares of Coya Therapeutics in a research note on Wednesday, August 12th. Roth Capital reiterated a "buy" rating and issued a $12.00 price target on shares of Coya Therapeutics in a report on Monday. Finally, Wall Street Zen lowered Coya Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, May 16th. Six equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $15.33.

Coya Therapeutics Trading Up 1.6%

Shares of NASDAQ COYA opened at $5.04 on Wednesday. The stock has a market cap of $118.24 million, a price-to-earnings ratio of -4.71 and a beta of 0.60. Coya Therapeutics has a 52 week low of $3.71 and a 52 week high of $7.75. The company's 50-day moving average price is $4.90 and its 200 day moving average price is $4.68.

Institutional Trading of Coya Therapeutics

Several large investors have recently bought and sold shares of the company. Alyeska Investment Group L.P. bought a new stake in shares of Coya Therapeutics in the fourth quarter worth $4,640,000. AWM Investment Company Inc. bought a new position in Coya Therapeutics during the 4th quarter valued at $4,205,000. CM Management LLC boosted its stake in Coya Therapeutics by 16.7% during the 4th quarter. CM Management LLC now owns 350,000 shares of the company's stock valued at $2,030,000 after acquiring an additional 50,000 shares during the last quarter. Private Management Group Inc. acquired a new position in Coya Therapeutics during the 4th quarter worth $1,626,000. Finally, Marshall Wace LLP increased its position in shares of Coya Therapeutics by 438.8% in the 4th quarter. Marshall Wace LLP now owns 225,358 shares of the company's stock worth $1,307,000 after purchasing an additional 183,533 shares during the last quarter. Institutional investors and hedge funds own 39.75% of the company's stock.

Coya Therapeutics News Summary

Here are the key news stories impacting Coya Therapeutics this week:

• Positive Sentiment: HC Wainwright maintained a “Buy” rating and raised its FY2026 EPS forecast to a loss of $1.30 from a prior loss of $1.52. The firm also improved its Q3 2026 estimate to a loss of $0.33 from $0.40 and lifted its Q4 2026 forecast to a loss of $0.36 from $0.44. HC Wainwright estimates
• Positive Sentiment: The analyst raised its FY2027 EPS outlook to a loss of $1.64 from $1.66, while improving its Q1 2027 and Q4 2027 forecasts. Although the company is still expected to report losses, the revisions imply a modestly better profitability trajectory. HC Wainwright earnings revisions
• Positive Sentiment: Roth Capital reaffirmed its “Buy” rating and set a $12.00 price target, substantially above the referenced $5.04 share price. Analysts overall assigned Coya an average target of $15.33, indicating significant perceived upside if the company executes on its development plans. Coya Therapeutics earns Buy rating from Roth Capital Coya Therapeutics average analyst price target
• Neutral Sentiment: HC Wainwright lowered its Q2 2027 EPS estimate to a loss of $0.48 from $0.46 and its Q3 2027 estimate to a loss of $0.40 from $0.39. These reductions partially offset the more favorable revisions elsewhere.
• Neutral Sentiment: Reported short interest was zero shares, leaving no meaningful short-covering or short-squeeze signal. Coya’s small market capitalization and continuing losses remain important risks despite the bullish ratings.

About Coya Therapeutics

Coya Therapeutics, Inc NASDAQ: COYA is a clinical‐stage biotechnology company focused on the discovery and development of first‐in‐class therapeutics for fibrotic diseases and cancer. The company's scientific approach centers on targeting UNC-45A, a molecular chaperone implicated in the regulation of cell motility, proliferation and extracellular matrix deposition. By modulating the activity of UNC-45A, Coya aims to address underlying mechanisms of tissue fibrosis and tumor progression that currently lack effective treatments.

Coya's pipeline is anchored by two lead programs: COY-001, a small‐molecule inhibitor in preclinical development for fibrotic disorders such as idiopathic pulmonary fibrosis and systemic sclerosis, and COY-002, which is being advanced toward the clinic for certain solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source